Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug540 | Berzosertib Wiki | 1.00 |
| drug2098 | Laboratory Biomarker Analysis Wiki | 1.00 |
| drug1249 | Docetaxel Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011471 | Prostatic Neoplasms NIH | 0.45 |
| D002277 | Carcinoma NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012125 | Prostate cancer HPO | 0.45 |
| HP:0030731 | Carcinoma HPO | 0.35 |
Navigate: Correlations HPO
There is one clinical trial.
The goal of this study is to test whether an online, self-administered SSI designed to strengthen perceived control over anxiety in the context of the COVID-19 pandemic (Contain COVID Anxiety) increases perceived control over anxiety more than a placebo, hand-washing-plan SSI (Remain COVID Free) in a weighted-probability sample of the United States (N = 500).
Description: ACQ is a 30-item questionnaire that measures an individual's level of agreement with a set of beliefs. Each item is scored on a scale from 0 (strongly disagree) to 5 (strongly agree) based on how much the statement is typical of the individual. The questionnaire measures domains of emotion control, threat control, and stress control, but only the emotion control scale (4 questions) will be used for the purposes of this study.
Measure: Change in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention Time: Baseline, immediately post-intervention, 2-week follow-upDescription: The GAD-7 asks participants to rate 7 statements based on how generally anxious they have felt over the past 2 weeks. Participants rate the 7 statements on a 4 point scale ranging from 0 (Not at all) to 3 (Nearly every day). Total score ranges from 0 to 21 with higher scores representing higher generalized anxiety.
Measure: Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up Time: Baseline, 2-week follow-upDescription: As validated measures for social distancing intentions do not yet exist, the 3 questions used in this measure are derived from the standardized item bank provided by the Center for Disease Control. The three questions ask participants to rate how long they believe others would be willing to engage in social distancing behaviors regarding large events, public spaces, and private gatherings. Participants rate the 3 statements on a 4 point scale ranging from 1 (Less than a Month) to 4 (4 months or more). Total score ranges from 4 to 12, with a higher score indicating greater levels of intention to socially distance.
Measure: Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention Time: Baseline, immediately post-interventionDescription: Derived from the CDC COVID-19 Community Survey Question Bank, participants will be asked to report whether they have been tested for COVID-19, tested positive for COVID-19, and displayed symptoms of COVID-19 in the past week. The questions also ask how the COVID-19 outbreak affected the participant in the past two weeks and if the children's schools are currently closed.
Measure: COVID-19 Related Questions Time: BaselineDescription: The IDAS is a screening tool for depression and panic disorder that asks people to rate how they have been feeling and acting in the past two weeks. Only the dysphoria subscale will be used; the subscale consists of 10 statements which the participants rate on a 1 (Not at all) to 5 (Extremely). Total score ranges from 10 to 50 for Dysphoria.
Measure: Inventory of Depression and Anxiety Symptoms (IDAS) Time: BaselineDescription: This brief measure asks participants to rate 7 statements measuring feelings of self-hatred on a 7-point Likert scale ranging from 1 (Not at all true for me) to 7 (Very true for me). Total score ranges from 7 to 49 with higher scores indicating higher levels of self hate.
Measure: Self Hate Scale (SHS) Time: BaselineDescription: Two multiple choice questions developed for the purpose of the study to serve as a quality check that ensures participants comprehended the core messages of both interventions.
Measure: Comprehension Questions Time: Immediately post-interventionDescription: The 5-item measure assesses chronic and routine unfair treatment in daily life on a scale from 1 - 5, with a total score between 5 and 25
Measure: Everyday Discrimination Scale-Short version Time: BaselineDescription: One question designed for use in this study. Participants rate their perceived changes in levels of generalized anxiety symptoms over 2 weeks from 1 (Much less anxiety) to 5 (much more anxiety)
Measure: Perceived Changes in generalized anxiety symptoms Time: 2-week follow-upDescription: This scale asks participants to rate 3 statements based on their intentions to engage in hand washing behaviors. Participants rate the 3 statements on a 7 point scale ranging from 1 (Strongly Agree) to 7 (Strongly Disagree). Total score ranges from 3 to 21, and will be reverse scored so a higher score indicates greater levels of intention to engage in recommended hand washing behaviors.
Measure: Activity Hand Washing Intentions - 3 item version (WASH-I) Time: Baseline, immediately post-interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports